tbuckley/cabot-search huggingface dataset:
Diagnosis and treatment of cancer‐related anemia
Authors: Jeffrey A. Gilreath, David D. Stenehjem, George M. Rodgers
Journal: American Journal of Hematology (2013)

Cancer-related anemia (CRA) is due to multiple etiologies, including chemotherapy-induced myelosuppression, blood loss, functional iron deficiency, erythropoietin deficiency due to renal disease, marrow involvement with tumor as well as other factors. The most common treatment options for CRA include iron therapy, erythropoietic-stimulating agents (ESAs), and red cell transfusion. Safety concerns as well as restrictions and reimbursement issues surrounding ESA therapy for CRA have resulted in suboptimal treatment. Similarly, many clinicians are not familiar or comfortable using intravenous iron products to treat functional iron deficiency associated with CRA. This article summarizes our approach to treating CRA and discusses commonly encountered clinical scenarios for which current clinical guidelines do not apply.
Abstract 639: Antibody-mediated blockade of phosphatidylserine combined with radiation improves survival and tumor eradication in a rat model of non-small cell lung cancer
Authors: Olivier Belzile, Zhang Zhang, Xianming Huang, Debabrata Saha, Rolf A. Brekken
Journal: Cancer Research (2014)

Abstract Stereotactic body radiation therapy (SBRT) uses image guidance to deliver very high doses of radiation, in no more than 5 fractions, to tumors. SBRT has shown remarkable benefit in patients with peripheral lung tumors but can cause severe toxicity to central organs when the tumor is proximally located if full potency doses are used (18 Gy x 3 fractions, for example). Bavituximab, a therapeutic monoclonal antibody that is headed to Phase III clinical trials, recognizes the immunosuppressive lipid, phosphatidylserine (PS), which becomes exposed on both tumor blood vessels and tumor cells subjected to SBRT. We hypothesized that treatment with the antibody 2aG4 (a murine version of bavituximab) would synergize with SBRT and allow tolerable doses of radiation to be used to treat centrally-located NSCLC without sacrificing efficacy. Nude rats bearing established orthotopic A549-luc NSCLC were treated with 3x12 Gy of radiation alone or combined with 2aG4 (4mg/kg) injected twice per week. Tumor growth was followed by bioluminescence. Rats treated with radiation and 2aG4 had a 100% survival rate 106 days after implantation and tumors were completely eradicated in 44% of these animals. In contrast, rats treated with radiation had a survival rate of 17% while only 11% of untreated rats survived. A toxicity study was conducted in which 3x12 Gy of radiation was delivered to central organs of tumor-free rats. This treatment does not appear to cause severe toxicity. These results suggest that bavituximab with radiation may result in improved clinical outcome in patients with centrally-located Non-Small Cell Lung Cancer (NSCLC). Citation Format: Olivier Belzile, Zhang Zhang, Xianming Huang, Debabrata Saha, Rolf A. Brekken. Antibody-mediated blockade of phosphatidylserine combined with radiation improves survival and tumor eradication in a rat model of non-small cell lung cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 639. doi:10.1158/1538-7445.AM2014-639
Primary Care Medicine: Office Evaluation and Management of the Adult Patient.
Authors: Allan H. Goroll, Albert G. Mulley
Journal: Annals of Internal Medicine (1991)

Principles of primary care systemic problems cardiovascular problems respiratory problems gastrointestinal problems haemotologic and onocolgic problems endocrinologic problems gynaecologic problems genitourinary problems musculoskeletal problems neurologic problems dermatologic problems ophthalmologic problems ear, nose and throat problems psychiatric and behavioural problems.
Single-institution experience of surgical management of metastasises of colorectal cancer in lungs: Lessons learned
Authors: Svetlana Grigorieva, Kuldash Abdumuradov, Arkadiy Bogov, Vladimir Parshin, Dmitry Bazarov
Journal: European Respiratory Journal (2013)

Background: Lungs are the most frequent localization of extraabdominal metastasises of a colorectal cancer (CCM). CCM possess insufficient sensitivity to chemotherapy in this connection surgical removal them is represented justified.  Aims: to study results of surgical management of metastasises of a colorectal cancer in lungs.  Materials and methods: 82 patients with CCM were operated. Age varied from 18 to 79 years. M - 53, f – 29. Histological diagnosis was adenocarcinoma in all cases. After inspection, in absence of local recurrence and metastasises in other sites, all patients were operated. On operations we held principles of sparing surgery: wedge resections made in 57 cases, lobectomy - in 25 cases. In 9 patients bilateral metastasises were found, in 7 of them operations made consistently, and two patients executed one-stage bilateral toracotomy with removal of CCM. Repeatedly concerning recurrence of CCM 8 patients were operated, from them 6 patients were operated twice and two - 3 times.  Results:Complication after operation were observed in 6 (7,5%) cases. We had9t lethality. Long-term results traced in 73 patients. 3-y and 5-y survival was 49,1% and 32,0% respectively. The best results are received after removal of solitary metastasises without lymph nodes involvment. More than 5 years were survived 38,2% of patients. Results were much worse during removal of multiple CCM and in case of lymph node defeat, the 5-year survival at these patients was 20,1%. Conclusions: Removal of lungs CCM as the part of the combined management in the absence of local recurrence and metastasises in other organs, allows to achieve, in some cases, long survival of patients.
Robotic Unclamped “Minimal-margin” Partial Nephrectomy: Ongoing Refinement of the Anatomic Zero-ischemia Concept
Authors: Raj Satkunasivam, Sheaumei Tsai, Sumeet Syan, Jean-Christophe Bernhard, Andre Luis de Castro Abreu, Sameer Chopra, Andre K Berger, Dennis Lee, Andrew J Hung, Jie Cai, Mihir M Desai, Inderbir S Gill
Journal: European Urology (2015)
Somatic activation of β-catenin bypasses pre-TCR signaling and TCR selection in thymocyte development
Authors: Fotini Gounari, Iannis Aifantis, Khashayarsha Khazaie, Sonja Hoeflinger, Naomoto Harada, Makoto M. Taketo, Harald von Boehmer
Journal: Nature Immunology (2001)
The Contribution of Smart Materials and Advanced Clinical Diagnostic Micro‐ Devices on the Progress and Improvement of Human Health Care
Authors: F.R.R. Teles, L.P. Fonseca
Journal: Advanced Healthcare Materials (2014)

This chapter contains sections titled: Introduction Physiological Biomarkers as Targets in Clinical Diagnostic Bioassays Biosensors Advanced Materials and Nanostructures for Health Care Applications Applications of Micro-Devices to Some Important Clinical Pathologies Conclusions and Future Prospects Acknowledgment
Butterworths Medical Dictionary.
Authors: MacNalty, Arthur Salusbury, Sir, Macdonald Critchley
Journal: Annals of Internal Medicine (1978)

This interesting and provocative book tries to set Greek ideas down to Aristotle on the heart, blood, and brain as the source of life within their general social and philosophical context, and to provide them with an anthropology.To do this, the authors employ a series of theoretical antinomies-e.g.heart/brain, technician/ prophet, democrat/oligarch, experience/intuition, sensation/intellect-some of which are more convincing than others.However, the traditional and unsatisfactory dichotomy between Coan and Cnidian medicine still lingers on, and there is little attempt to see whether there is any development over time in any of the ideas in the
Transplantable Malignant Tumors in Mice Induced by Preparations Containing Ribonucleic Acid Extracted From Human and Mouse Tumors&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Fanny Lacour, Jean Lacour, Jacques Harel, Joseph Huppert
Journal: JNCI Journal of the National Cancer Institute (1960)
TIMP-4 promotes brain tumor cell survival by regulation of AKT pathway
Authors: Jennifer Adjodha, Yasar Celiker, Mark Mittler, Eric Shi, Jeffrey Lipton
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4380 

Tissue inhibitor of metalloproteinase 4 (TIMP4 ) is a recently cloned member of the TIMP family which regulate the activity of several of the matrix metalloproteinases (MMPs ). Several studies show that TIMP4 affects many properties of tumorogenesis including cell proliferation and apoptosis, in several types of cancer. However, the molecular mechanism underlying growth regulation and apoptosis by TIMP4 has not been determined. We have previously shown that TIMP-4 increases proliferation of SF-268 glioblastoma cells in-vitro. In this study, we show that TIMP4 increases AKT activation in the SF-268 glioblastoma cell line. We also demonstrate that TIMP4 protects glioblastoma cells from adriamycin induced cell killing This data suggests that TIMP-4 may play an important role in brain tumor survival through the regulation of the PI3K/AKT signaling pathway.
L’Île Lacroix, Rouen (The Effect of Fog)
Authors: M Therese Southgate
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New Misconduct Rules
Authors: Brian Vastag
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Gynecologic Oncology Group randomized trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide+mesna (CIM) in optimally debulked stage I-IV carcinosarcoma (CS) of the uterus
Authors: A. H. Wolfson, M. F. Brady, R. S. Mannel, Y. Lee, R. J. Futoran, D. Cohn, O. B. Ioffe, T. F. Rocereto
Journal: Journal of Clinical Oncology (2006)

5001 Background: Besides initial surgery, there has been no established consensus regarding adjunctive therapy for optimally debulked patients with uterine CS. This study was designed to compare progression-free interval (PFI), overall survival (OS), toxicity, and failure patterns using WAI vs CIM chemotherapy for this uncommon group of female malignancies. Methods: Patients with stage I-IV disease, ≤ 1 cm residual tumor, and no extra-abdominal involvement were randomly assigned to either WAI (approximately 30 Gy followed by pelvic boost) or cisplatin 20 mg/m 2 /d × 4, ifosfamide 1.5 g/m 2 /d × 4 and mesna 120 mg/m 2 loading dose, then 1.5 g/m 2 /d × 24 h, repeated q 3 weeks × 3 cycles. Results: 224 patients were enrolled, of whom 207 (WAI = 105; CIM = 102) were eligible. Patient demographics and characteristics were similar between arms. FIGO stage (both arms) was: I = 64 (31%); II = 26 (12%); III = 93 (45%); IV = 24 (11%). GI toxicity ≥ grade 2 occurred frequently and similarly (31%, both arms). CIM was associated with more ≥ grade 3 anemia (11% vs 1%) and neurotoxicity (9% vs 0%) compared to WAI. Two deaths were attributed to RT-induced hepatitis. Sites of first recurrence in WAI vs CIM among the 97 (47%) patients who relapsed were: vagina, 4 vs 10; pelvis, 12 vs 12; abdomen, 23 vs 14; lung, 13 vs 13; other, 13 vs 9. The estimated probability of recurring within 5 years is 55% (WAI) and 49% (CIM). Adjusting for stage, the recurrence rate was 28.5% lower for CIM patients relative to WAI patients (hazard ratio [HR]: 0.715, 95% confidence interval [CI]: 0.474–1.077, p = 0.108, 2-tail test). The estimated death rate for CIM is 32.8% lower relative to WAI (HR: 0.672, 95% CI: 0.458–.986, p = 0.042). Conclusion: Compared to WAI, adjuvant CIM reduces the recurrence rate and significantly prolongs OS in optimally debulked uterine CS patients; however, due to a high relapse rate and poor OS, the imperative for new adjuvant therapies remains. No significant financial relationships to disclose.
Mucosal Biopsy of the Gastrointestinal Tract.
Authors: R Whitehead
Journal: Annals of Internal Medicine (1974)

This is the third edition of the standard bench book for the interpretation of biopsies of the gastrointestinal tract. Revised and updated, the book covers all the recent developments in the classification and identification of new aspects of mucosal disease. Oesophageal, gastric, and small intestinal biopsies are detailed.
Abstract 2606: Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGF-R but not the K-RAS/B-RAF mutational status in colorectal cancer
Authors: Yoshiyuki Ishii, Yuki Seo, Shingo Akimoto, Kazumasa Fukuda, Tetsu Hayashida, Koji Okabayashi, Masashi Tsuruta, Hirotoshi Hasegawa, Yuko Kitagawa
Journal: Cancer Research (2014)

Abstract Cetuximab, an IgG1 monoclonal antibody against epidermal growth factor receptor (EGF-R), is widely used for the treatment of metastatic colorectal cancer (mCRC). One of the working mechanisms is considered to be antibody-dependent cell-mediated cytotoxicity (ADCC) triggered by Fcγ−R on natural killer cells. However, whether ADCC is associated with EGF-R expression and/or the mutational status of EGF downstream effectors (K-RAS and B-RAF etc.) in colorectal cancer (CRC) remains unclear. The aim of this study was to verify whether ADCC activities are associated with the cell surface expression levels of EGF-R and/or the mutational status of K-RAS and B-RAF. Five human CRC cell lines with different cell surface expression levels of EGF-R and different K-RAS and B-RAF mutational statuses were selected to evaluate ADCC activity using peripheral blood mononuclear cells (PBMC) from healthy human donors. Furthermore, tumor cells from resected specimens of CRC patients were used to evaluate the cell surface expression level of EGF-R using immunohistochemistry and the K-RAS and B-RAF mutational statuses using direct sequencing, while the ADCC activity was examined using PBMCs from the same CRC patients. A strong correlation was observed between the expression levels of EGF-R and the ADCC activities in the cell lines (correlation coefficient: 0.949; P = 0.003). Of the 13 resected specimens, a high ADCC activity level was significantly observed in tumor cells with high expression levels, compared with those with low expression levels, of cell surface EGF-R (P = 0.027). In both CRC cell lines and tumor cells from CRC patients, the ADCC activities were significantly associated with the cell surface expression levels of EGF-R (standard partial regression coefficients: 0.911 [P = 0.017] and 0.660 [P = 0.018], respectively), but not the mutational status of K-RAS and B-RAF (standard partial regression coefficient: -0.101 [P = 0.631] and 0.160 [P =0.510], respectively). Cetuximab-mediated ADCC activity may be correlated with the cell surface expression level of EGF-R, regardless of the mutational statuses of K-RAS and B-RAF, in CRC. Citation Format: Yoshiyuki Ishii, Yuki Seo, Shingo Akimoto, Kazumasa Fukuda, Tetsu Hayashida, Koji Okabayashi, Masashi Tsuruta, Hirotoshi Hasegawa, Yuko Kitagawa. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGF-R but not the K-RAS/B-RAF mutational status in colorectal cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2606. doi:10.1158/1538-7445.AM2014-2606
The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM
Authors: Johan P. de Winter, Martin A. Rooimans, Laura van der Weel, Carola G.M. van Berkel, Noa Alon, Lucine Bosnoyan-Collins, Jan de Groot, Yu Zhi, Quinten Waisfisz, Jan C. Pronk, Fré Arwert, Christopher G. Mathew, Rik J. Scheper, Maureen E. Hoatlin, Manuel Buchwald, Hans Joenje
Journal: Nature Genetics (2000)
An Electron Microscope Study of NK Lymphoma Cells and the Changes Produced by Two Cytostatic Drugs
Authors: K. Lapis, E. H. Mercer
Journal: Cancer Research (1963)

Summary  The ultrastructure of the NK/Ly mouse ascites lymphoma cell and the alterations caused by two alkylating agents, mannomustine (Degranol) and cyclophosphamide (Endoxan), are described. Cells were examined at different times following treatment in order to follow the degenerative and regenerative changes.  NK/Ly lymphoma cells resemble both normal lymphoid cells and also other types of ascites cells.  Treatment by the cytostatic drugs caused typical but not specific degenerative changes. During the recovery period larger cells, sometimes multinucleate with large rather empty mitochondria, appeared.  Virus particles were found in the Golgi region of many cells, particularly after exposure to the drugs. These particles resemble oncogenic viruses, but their relation to these is obscure, and it has not yet proved possible to transfer the NK lymphoma by cell-free filtrates.
Abstract 12703: Antiepileptic Medicines is Associated With Brugada-Type ST Elevation in Patients With Epilepsy
Authors: Naruya Ishizue, Shinichi Niwano, Masanori Saitou, Tazuru Igarashi, Tamami Fujiishi, Tomoharu Yoshizawa, Jun Kishihara, Masami Murakami, Hidehira Fukaya, Hiroe Niwano, Hitoshi Miyaoka, Junya Ako
Journal: Circulation (2014)

Purpose: Some of psychotropic medicines are known to cause ECG changes such as QT prolongation. Because some of antiepileptic medicines have sodium or calcium channel blocking effects, they may lead to manifestation of Brugada-type ST elevation or J-wave like inter-ventricular conduction delay. In the present study, we focused on the patients with epilepsy who have continued to take antiepileptic medicines, and the prevalence of Brugada-type ST elevation was evaluated in their ECG. Method: The study population consisted of 120 consecutive patients with epilepsy who have continued to take more than one of antiepileptic medicines (carbamazepine 63, phenytoin 43, valproic acid 50, phenobarbital 10 and the others 23 patients) and have analyzable ECG recordings during these therapies. Brugada-type ST elevation was classified into type 1-3 in accordance with the consensus report of Brugada syndrome. Results: Out of 120 patients, 15 (12.5%) exhibited Brugada-type ST elevation (type 1 6.67%, type2 20.0%, and type...
A Text-Book of Diseases of Women.
Authors: Lewis S. Pilcher
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Assessment of Coronary Artery Stenosis Severity and Location
Authors: Amedeo Chiribiri, Gilion L.T.F. Hautvast, Timothy Lockie, Andreas Schuster, Boris Bigalke, Luca Olivotti, Simon R. Redwood, Marcel Breeuwer, Sven Plein, Eike Nagel
Journal: JACC. Cardiovascular imaging (2013)
Genomic Organization, Chromatin Structure, and Transcriptional Regulation of the Murine Alpha Hemoglobin Stabilizing Protein (AHSP) Gene.
Authors: Louis C. Dore, Christopher R. Vakoc, Gerd A. Blobel, Ross C. Hardison, David M. Bodine, Patrick G. Gallagher, Mitchell J. Weiss
Journal: Blood (2005)
Editing embargo is bad news for US scientists too
Authors: Sergio A Perez Barrero
Journal: BMJ (2004)

Research on preventing road traffic injuries in developing countries is neededEditor-The dedication of the World Health Organization's World Health Day 2004 to road safety is recognition of the global threat of road traffic injuries.Increasing population size, vehicle ownership, road infrastructure, and transnational transportation have created a substantial public health burden.However, little epidemiological research has been conducted into preventing road traffic injuries in developing countries.Currently global research and development funding per disability adjusted life year for HIV, asthma, and blindness are $26.2,$10.8, and $5.4, respectively, while only $0.40 for road traffic injuries. 1 Epidemiological studies of successful interventions preventing road traffic injuries have been conducted in developed countries. 2But to assume the same effectiveness in developing countries is inappropriate because of behavioural, vehicular, and environmental differences.A pooled analysis of street lighting intervention data from developed countries shows a protective effect, 3 particularly in pedestrian injury (relative risk 0.56), the most common road traffic injuries in developing countries.Annually, 1.2 million deaths are attributed to road traffic crashes, 85% occurring in developing countries. 4If an intervention such as street lighting could reduce deaths by as much as 30%, there is a potential to save thousands of lives.Various international aid agencies are investing in road infrastructure development.These initiatives could be coupled with the need to develop concrete epidemiological data.Innovative strategies, such as step wedge study design, 5 could lead to the evolution of an evidence based public health approach to this problem.